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Clinical and Genetic Findings of Five Patients 
with WT1-Related Disorders
ABSTRACT 
Aim: To present phenotypic variability of WT1-related disorders. Methods: De-
scription of clinical and genetic features of fi ve 46,XY patients with WT1 anom-
alies. Results: Patient 1: newborn with genital ambiguity; he developed Wilms 
tumor (WT) and chronic renal disease and died at the age of 10 months; the 
heterozygous 1186G>A mutation compatible with Denys-Drash syndrome was 
detected in this child. Patients 2 and 3: adolescents with chronic renal dis-
ease, primary amenorrhea and hypergonadotrophic hypogonadism; patient 2 
had a gonadoblastoma. The heterozygous IVS9+4, C>T mutation, compatible 
with Frasier syndrome was detected. Patient 4: 9-year-old boy with aniridia, 
genital ambiguity, dysmorphisms and mental defi ciency; a heterozygous 11p 
deletion, compatible with WAGR syndrome was detected. Patient 5: 2 months 
old, same diagnosis of patient 4; he developed WT at the age of 8 months. 
Conclusions: Constitutional abnormalities of WT1 cause gonadal and renal 
anomalies and predisposition to neoplasia and must be investigated in patients 
with ambiguous genitalia, chronic renal disease and(or) Wilms tumors; primary 
amenorrhea with chronic renal disease; and aniridia, genital ambiguity and 
dysmorphisms. (Arq Bras Endocrinol Metab 2008; 52/8:1236-1243)
Keywords: Sex differentiation; WT1 gene; Denys-Drash syndrome; Frasier 
syndrome; WAGR syndrome
RESUMO
Achados Clínicos e Genéticos de Cinco Pacientes com Anomalias 
Relacionadas ao Gene WT1.
Objetivo: Descrever a variabilidade fenotípica das anomalias relacionadas ao 
WT1. Métodos: Descrição das características clínicas e genéticas de cinco pa-
cientes 46,XY com anomalias no WT1. Resultados: Paciente 1: Recém-nascido 
com ambigüidade genital desenvolveu tumor de Wilms (TW) e insufi ciência 
renal crônica (IRC), com óbito aos 10 meses. Detectada a mutação 1186G>A 
em heterozigose, compatível com síndrome de Denys-Drash. Pacientes 2 e 3: 
Adolescentes com IRC, amenorréia primária e hipogonadismo hipergonado-
trófi co; a paciente 2 apresentava gonadoblastoma. Ambas apresentavam 
mutação IVS9+4, C>T em heterozigose, característica da síndrome de Frasier. 
Paciente 4: Idade 9 anos, aniridia, ambigüidade genital, dismorfi smos e defi -
ciência mental; deleção 11p, compatível com síndrome WAGR foi encontrada 
em heterozigose. Paciente 5: Dois meses, mesmo diagnóstico do paciente 4, 
desenvolveu TW aos 8 meses. Conclusões: Alterações constitucionais do 
WT1 determinam anomalias gonadais, renais e predisposição a neoplasias; 
devem ser pesquisadas em casos de ambigüidade genital associada a IRC 
e(ou) TW; de amenorréia primária com IRC; e aniridia, ambigüidade genital e 
dismorfi smos. (Arq Bras Endocrinol Metab 2008; 52/8:1236-1243)
Descritores: Diferenciação sexual; Gene WT1; Síndrome de Denys-Drash; 
Síndrome de Frasier; Síndrome WAGR
































sex ambiguity as a result of dysgenetic testis, diffuse 
mesangial sclerosis with chronic renal disease and high 
incidence of Wilms tumour (WT) (13-14). The clinical 
picture of FS includes dysgenetic gonads with male-to-
female sex reversal in 46,XY subjects and pubertal delay 
in both sexes, nephrotic syndrome and focal segmental 
glomerulosclerosis leading to chronic renal disease , 
and high incidence of gonadoblastoma but not of WT. 
Mutations in FS affect the splice site in intron 9, with 
WT1(+KTS) isoforms (15-16) losses.
WAGR (WT, aniridia, genitourinary malformations, 
mental retardation) is a contiguous gene syndrome ari-
sing from deletions of chromosome 11p13 which en-
compass at least both the PAX6 and WT1 genes 
(17-19).
We report fi ve patients followed in a reference ser-
vice for disorders of sex development which illustrate 




The fi ve patients were evaluated by the Interdisciplina-
ry Study Group of Disorders of Sex Development 
(GIEDDS) of the State University of Campinas, São 
Paulo. The protocol was approved by the local Ethics 
Committee (N. 434/06) and informed consent was 
obtained from the parents of the children included in 
the study.
Laboratory assays
LH, FSH, testosterone were measured by electroche-
miluminescence (BM/Hitachi Elecsys 2010, Roche 
Diagnostics, Boehringer, Mannheim, Germany).
Karyotype
Chromosome analysis of peripheral blood lymphocytes 
was performed by G-banding at 500-600 bands resolu-
tion using standard procedures.
Genomic DNA extraction, amplifi cation 
and sequencing
Genomic DNA from peripheral blood leukocytes was 
purifi ed by Proteinase K digestion and phenol/chloro-
form extraction followed by ethanol precipitation using 
standard techniques (20). 
INTRODUCTION
Sex determination is a complex and yet not fully elu-cidated process which depends on a complex ne-
twork of interrelated genes. Gonadal development 
starts by the end of the 5th week of gestation with the 
migration of primordial germ cells from the yolk sac to 
the gonadal anlage. Formation of the primordial gona-
ds, which have no apparent sexual differences up to 8 
weeks, depend on the expression of many genes, inclu-
ding SF-1 (steroidogenic factor 1) (1), DAX1 (dosage-
sensitive sex reversal, adrenal hypoplasia critical region, 
on chromosome X, gene 1) (2) and WT1 (Wilms tu-
mour 1) (3).
WT1 (OMIM 607102) is located at 11p13 and en-
codes a zinc fi nger motif-containing transcription factor 
involved in regulation of growth and differentiation (4). 
Beyond its role in the genesis of Wilms tumour (5-6), it 
regulates early gonad and kidney development (7). 
Alternative splicing generates four major WT1 iso-
forms: an alternative splice site in intron 9 allows the 
addition of three amino acids (KTS) between zinc fi n-
gers 3 and 4 and the fi fth exon, encoding 17 aminoaci-
ds, may or may not be present. These isoforms are 
highly conserved among different species and play a 
crucial role in normal gene function. Gene action de-
pends on the predominant isoform: WT1 (-KTS) va-
riants act as transcriptional regulators, while WT1 
(+KTS) participates on the regulation of certain genes 
at the post-transcriptional level (8-10).
WT1 (-KTS) isoforms act in association with the 
product of SF-1 to promote expression of anti-mülle-
rian hormone (AMH), responsible for regression of the 
müllerian ducts in male embryos. The product of DAX1 
can repress the synergistic action of WT1 and SF-1, re-
sulting in down-regulation of AMH (11). In vitro ex-
periments suggested that WT1 (-KTS) variants are also 
responsible for transcriptional activation of SRY, which 
activates the male differentiation pathway (10).
Mutations in WT1 are found in a variety of syndro-
mes, including Denys-Drash (DDS, OMIM 194080), 
Frasier (FS, OMIM 136680) and WAGR (OMIM 
194072) syndromes. Both DDS and FS are characterized 
by gonadal and renal anomalies and predisposition to ne-
oplasia associated with “de novo” constitutional WT1 
point mutations with a negative dominant effect (12).
In DDS, mutations often occur in the zinc fi nger 
region abolishing DNA binding capacity and leading to 
































The 10 exons and the exon-intron junction regions 
of the WT1 gene were PCR amplifi ed from genomic 
DNA with primers described in Table 1. Genomic se-
quence of the WT1 gene was obtained in the published 
sequence ENSG00000184937 (www.ensembl.org).
The fi nal volume of all reactions was 50 uL and con-
tained 10X Taq DNA polymerase buffer (Invitrogen, 
CA, USA), 1.0-1.5 mM MgCl2, 2 mM of each dNTP, 
20 pmol of each primer, 300-500 ng genomic DNA 
templates 2 units recombinant Taq DNA polymerase 
(Invitrogen), 5% DMSO used only for exon 1. After a 
fi rst denaturation step (5 min, 94°C), the cycling profi le 
was: 94°C, 1 min; 53,5°C – 63,5°C, 1 min; 72°C 1-6 
min (30 cylcles), followed by 5 min at 72°C (fi nal exten-
sion). The size of the PCR products was verifi ed in 1% 
agarose gel electrophoresis stained with ethidium bromi-
de. Before sequencing, purifi cation of PCR products was 
performed using the Wizard® SV Gel and PCR clean-up 
system (Promega, Madison, WI, USA). Further direct 
sequencing using ABI PRISM Big Dye Terminator v3.1 
Cycle Sequencing Kit (ABI PRISM/PE Biosystems, 
Foster City, CA, USA) was carried out in two separate 
reactions for each exon, except for exon 1 which requi-
red four reactions, using sense and antisense primers 
(Table 1). The sequences were obtained in an automatic 
sequencer ABI PRISM 3700 DNA Analyzer (ABI 
PRISM/PE Biosystems). Free softwares Chromas Lite 
and CLC Sequence Viewer v.5.0.1 were used to analyze 
and compare sequences with the published WT1 sequen-
ce at Ensembl database.
RESULTS
Case 1
A 1-month-old child was referred to us due to sex am-
biguity. He was born at term after an uneventful preg-
Table 1. Primers designed for WT1 coding sequence amplifi cation.
Primer Direction Sequences 5’-3’ nt 2 Ta (°C)3 Size (bp)4
Exon 1 Forward TGAGTGAATGGAGCGGCCGAG 512-532 60.5 1049
Reverse TTGGGAAGCAGCTGGGTAAGAG 1539-1560
Intron 1Int 1 Forward TTCATCAAACAGGAGCCGAG 1211-1230
Intorn 1Int1 Reverse AAAGTGGACAGTGAAGGCGC 1269-1288
Exon 2-3 Forward CTGTCCCAAGGTCACATCCAG 7324-7344 57.5 1015
Reverse AAGTAGTAGAGTGGAGTCGAGGC 8313-8338
Intorn 2Int1 Reverse ATTTGCTGTGGGTTAGGAATTC 7710-7731
Intron 2Int1 Forward GGCTTAGCTTCTTGCATTCTG 7921-7941
Exon 4-5 Forward GATTTGCATATTCTGTCATTCTG 18351-18373 53.4 1406
Reverse ATGCTACCCTGATTACCCACG 19737-19757
Intron 4Int1 Reverse AAGCGTTCTAATGTCACAGAGAG 18678-18700
Intron 4Int1 Forward GCACTCTTGATAGCTAGCTTGATG 19475-19498
Exon 6 Forward TGCATCTAAAGTGGCCCCATG 35945-35965 57.5 375
Reverse AAAGGAGCCTGCAGTGAAGAAG 36298-36319
Exon 7 Forward TGGGGATCTGGAGTGTGAATG 39586-39606 56.6 442
Reverse TCTTTACAACACCTGGATCAGACC 40004-40027
Exon 8-9 Forward TACCCTAACAAGCTCCAGCG 43258-43277 55,1 1037
Reverse TCTCTCAACTGAGTCTAAACCTTAG 44271-44295
Intorn 8Int1 Reverse GAGAATCATGAAATCAACCCTAG 43522-43544
Intron 8Int1 Forward TGAGGCAGATGCAGACATTG 43949-43968
Exon 10 Forward CGGGCCTTGATAGTTGAACTTG 46892-46913 56.1 890
Reverse GTTTCTTAAGAGCAGTGTGCCAG 47759-47781
1Internal primers used only for sequencing; 2nucleotide position in the sequence ENSG00000184937; 3Anealing temperature used in PCR; 4size of amplifi ed fragments.
































nancy with a birth weight of 3,655 g and length 50 cm. 
He was the second child of unrelated parents and fami-
ly history was unremarkable. He had a 2-cm phallus 
with chordee, penoscrotal hypospadias, shawl scrotum, 
bilateral cryptorchidism, and there was no dysmorphic 
picture associated to sex ambiguity. Sonography revea-
led no mullerian derivatives while genitography showed 
a urogenital sinus. 
His karyotype was 46,XY, and there were normal 
basal levels of LH (5.4 U/L), FSH (3.8 U/L), free 
(5.4 pg/mL) and total (157 ng/dL) testosterone (T). 
When the child was 6 months old, a hCG stimulation 
test was performed (three intramuscular injections of 
Chorionic Gonadotropin (Profasi®, 1,000 IU, on suc-
cessive days), and testosterone levels increased from 
157 to 395 ng/dL. He developed unilateral WT and 
chronic renal disease at 8 months, and died 2 months 
later as a result of septicemia.
An 1186G>A heterozygous mutation was detected 
in exon 9 and confi rmed the diagnosis of DDS; this 
case was fi rst reported by Tagliarini and cols. (21).
Case 2
A 17.3-year-old girl was evaluated for primary amenor-
rhea and hypergonadotrophic hypogonadism. She was 
born at term after an uneventful pregnancy, with a bir-
th weight of 3,560g and length 46cm. She was the se-
cond child of unrelated parents, and family history was 
unremarkable. She was subject to renal transplantation 
at 11 years as a consequence of chronic renal disease; at 
the same age, bilateral inguinal hernia repair was per-
formed. 
She referred spontaneous pubertal onset. On phy-
sical examination, she had normal external genitalia 
and pubertal development was on Tanner stage B3P2. 
There was no dysmorphic picture. Ultrasound revealed 
a 2.8cm3 uterus, and gonads could not be found.
Her karyotype was 46,XY, and there were high le-
vels of FSH (188 U/L) and LH (46 U/L) and low 
estradiol (11pg/mL). Bilateral gonadectomy was per-
formed, and histology revealed a right dysgenetic go-
nad with mesonephric remnants and a gonadoblastoma 
on the left. Female hormonal replacement therapy was 
initiated later on. Molecular analysis revealed an 
IVS9+4, C>T heterozygous mutation in intron 9 (Fi-
gure 1), thus confi rming the diagnosis of Frasier syn-
drome.
Case 3
A 18-year-old girl was referred with a suspected diag-
nosis of FS to molecular analysis. She was the second 
child of unrelated parents, and family history was unre-
markable. The girl had chronic renal disease treated 
with peritoneal dialysis, and primary amenorrhea was 
investigated when she was 15 years old – cytogenetic 
investigation revealed a 46,XY karyotype, bilateral go-
nadectomy was performed and histology revealed dys-
genetic gonads. She has been on HRT since then.
On physical examination, she had no dysmorphic 
picture, external genitalia were normal, and breast de-
velopment was incomplete. 
Molecular analysis revealed the same mutation of 
case 2, thus confi rming the diagnosis of FS.
Case 4
A 9-year-old boy presented with a history of sex ambi-
guity, aniridia, mental and motor retardation and dys-
morphic features. He was born at term by cesarian 
section for breech presentation, after an uneventful 
pregnancy, with a birth weight of 2,550g. He was the 
Figure 1. A) The 1037-bp exon 8-9 fragment was amplifi ed by polymerase chain reaction (PCR). L- 1 kb-Plus Ladder (Invitrogen); 
patient (1), normal control (2), control without DNA (3); B) Eletropherogram of exon 9 sequence showing the C>T heterozygous 
mutation on WT1 intron 9. The KTS motif and the positions of alternative splicings are denoted.
































fi rst child in a sibship of three; his parents were not re-
lated, and family history was unremarkable.
Physical examination revealed fl at occiput, small 
and dysmorphic ears, short upslanted palpebral fi ssures, 
aniridia, nystagmus, short nose with high nasal bridge, 
clinodactyly of the V fi ngers, bilateral single transverse 
palmar crease, predominance of arches on the fi nger-
tips, fusiform fi ngers, nail hypoplasia, increased inter-
mamillary distance and diastasis recti. He had a 
4.5cm-phallus, bifi d scrotum, penoscrotal hypospadia 
and nonpalpable gonads.
Ophthalmologic evaluation revealed macular hypo-
plasia. The testes were not seen on pelvic ultrasound 
and genitography did not reveal a urogenital sinus. 
He had prepubertal levels of LH (<0.2 U/L), FSH 
(0.4 U/L), total (<20 ng/dL) and free (1 pg/mL) tes-
tosterone. An hCG stimulation test was performed, 
and testosterone levels increased from <20 to 396 ng/
dL. Cytogenetic investigation revealed a de novo 
46,XY,del(11p) karyotype, thus leading to the diagno-
sis of WAGR syndrome.
Case 5
A 3-month-old boy was evaluated for aniridia and 
dysmorphic features. He was born in the 38th week 
of gestation by cesarian section, and intrauterine 
growth retardation was noted at the 7th month. Birth 
weight was 2,650g and length 44cm. He was the 
only child of unrelated parents, and family history 
was unremarkable.
On physical examination, he presented high fo-
rehead, low anterior hairline, dysmorphic ears, ante-
verted nostrils, notched alae nasi, long and fl at 
philtrum, thin upper lip, retrognathism, short neck, 
single transverse palmar crease and hypoplastic nails. 
He had a 3.5-cm phallus, bilateral cryptorchidism and 
hypoplastic scrotum. Ophthalmologic evaluation re-
vealed photophobia, nystagmus, remnants of pupilla-
ry membrane and peripheral iris and mottled retinal 
pigment epithelium.
He had normal levels of LH (9.5 U/L), FSH (8.8 
U/L), and total testosterone (669 ng/dL) for age. His 
karyotype was 46,XY,del (11p) de novo (Figure 2), lea-
ding to the diagnosis of WAGR syndrome. When he 
was 8 months old, a unilateral Wilms tumour was de-
tected by sonography. He was subject to nephrectomy, 
chemotherapy and radiotherapy. There was no tumor 
relapse until the age of 4 years, and renal function re-
mained normal. Data on these fi ve cases are summari-
zed in Table 2.
Figure 2. Karyotype of patient 5.
del (11p)






































Clinical picture Neoplasia WT1 Diagnosis




















4 9 y M
Aniridia, perineal hypospadia, BL 
cryptorchidism, dysmorphic picture, motor 
and speech delay, mental defi ciency
– 11p13 deletion WAGR
5 2 mo M
Aniridia, BL cryptorchidism, dysmorphic 
picture, motor and speech delay
Wilms tumour 11p13 deletion WAGR
BL = bilateral; ESRD = end stage renal disease; F = female; L = left; M = male; NB = newborn; *deceased (10 months)
DISCUSSION
Disorders of gonadal development (DGD) are a highly 
heterogeneous group of disorders of sex development 
(DSD) and include individuals with dysgenetic gonads 
(streaks), dysgenetic or rudimentary testes and true 
hermaphroditism or ovotesticular DSD. Some 46,XY 
individuals with DGD are born with sex ambiguity, and 
thus may be evaluated in infancy. However, those with 
female internal and external genitalia (male-to-female 
sex reversal) may be diagnosed only in adolescence be-
cause of pubertal delay. The latter are of great concern 
because of the risk of neoplastic transformation of dys-
genetic gonads, which is signifi cantly elevated after 
adolescence (22). Hormonal activity of gonadoblasto-
ma may be found in some patients (23); in case 2, for 
instance, there was spontaneous breast development 
which may be due to an estrogen-producing gonado-
blastoma.
Among DGD, WT1-related disorders are characte-
rized by the association of gonadal and renal anomalies. 
As a consequence, screening for mutations in WT1 
should be considered in 46,XY patients with ambiguous 
genitalia associated with chronic renal disease and (or) 
WT and in 46,XY females with hypergonadotrophic 
hypogonadism and history of chronic renal disease, 
thus allowing the diagnosis of DDS and FS. 
In addition, all newborns with aniridia who do not 
have a family history of this ocular anomaly must be 
subject to high-resolution cytogenetic testing, which 
detects deletions involving 11p13 in up to 20% of indi-
viduals (24). FISH testing with probes spanning PAX6, 
WT1, the regions fl anking PAX6, and the intervening 
sequence between PAX6 and WT1 can also be used 
to detect cryptic deletions in individuals with other 
clinical features of WAGR and normal cytogenetic 
studies (24).
Genotype-phenotype correlations in WT1-related 
disorders are well established. Mutations in DDS pa-
tients inactivate DNA binding by the zinc fi ngers, le-
ading to early and severe impairment of renal function, 
dysgenetic testes and high incidence of WT, while in 
FS mutations in the donor splice site of intron 9 of 
the WT1 gene lead typically to dysgenetic gonads, 
end-stage renal failure in the second decade and go-
nadoblastoma. In turn, the reduced haploinsuffi -
ciency of WT1 in 11p13 deletion has a less pronounced 
effect on development, especially on that of the renal 
system. 
However, there are some reports of atypical pre-
sentations, including a 46,XY child with sex ambiguity, 
nephrotic syndrome, gonadal tumour and normal tes-
tosterone production despite high levels of gonadotro-
pins, who had a mutation associated with FS (25), In 
another study, a 46,XY child with sex ambiguity, nor-
mal testosterone production, aortic coarctation and no 
renal disease was found to have a P181S mutation in 
WT1 inherited from the mother (26).
Diagnosis of WT1-related disorders is more diffi -
cult in 46,XX subjects, who lack features of sex ambi-
guity and sex reversal. However, clinicians must have in 
mind that WT1 mutations may be found in up to 5% of 
































cases of steroid-resistant nephrotic syndrome (SRNS) 
(27-28). Routine evaluation of patients with this syn-
drome would allow early diagnosis of both DDS and 
FS in both sexes. 
The heterozygous 1186G>A (D396N) mutation 
in exon 9 of patient 1 leads to an aspartic acid-aspara-
gine substitution changing the structural organization 
of the third zinc fi nger of the WT1 protein. It was 
described in 1991 (13) and is a frequent fi nding in 
DDS; the most frequent mutation is 1180C>T 
(R394W) (39.6%) (29). The apparent dominant-ne-
gative nature of DDS mutations results from the ac-
tion of altered WT1 in blocking the normal activity of 
the wildtype protein (12).
The heterozygous mutation in intron 9 found in 
both patients with FS (IVS9+4, C>T) is the most fre-
quent mutation identifi ed in these patients (52%) 
(15,25). This and the other four different mutations 
described in intron 9 of WT1 in patients with FS lead to 
reversal of the (+KTS)/(-KTS) ratio from 2:1 to 1:2 
(15-16). Most of the patients with FS show the +4 C>T 
and +5G>A mutations; this hotspot is probably a con-
sequence of the potential to deaminate 5-methylcytosi-
ne at the +4/+5 CpG dinucleotide (16).
Recurrence risk of WT1-related disorders varies ac-
cording to each specifi c situation. DDS and FS usually 
arise as a consequence of de novo mutations, while 11p 
deletion in WAGR syndrome may be de novo or may 
result from transmission by a parent with a balanced 
chromosome rearrangement (24).
In conclusion, constitutional abnormalities of WT1 
should be considered in patients with ambiguous geni-
talia and renal disease (chronic renal disease or Wilms 
tumors), primary amenorrhea with chronic renal disea-
se, and those with aniridia, genital ambiguity and dys-
morphic picture with or without WT.
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